Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Feb 20, 2024 (3 years ago)

Clindamycin Phosphate

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Defective Container: Out of specification for weight due to a slow leakage at the 12-month stability timepoint.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Clindamycin Phosphate, Topical Solution USP, 1%, 60 mL, Rx Only, Manufactured for and Distributed by: Marlex Pharmaceuticals, Inc., New Castle, DE 19720, NDC 10135-0691-61

Affected NDC 10135-0691-61

Compare with the code on your package — it is the most precise check available.

Drug: Clindamycin Category: Antibiotic

Recalling firm
Contract Pharmaceuticals Limited Canada
NDC code
10135-0691-61
Origin
Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0364-2024 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Clindamycin recalls

See all

Other recalls by Contract Pharmaceuticals Limited Canada

All 2024 recalls